As part of our national accreditation through the American College of Surgeons, our breast program is charged with adopting national standards for screening mammography and communicating these standards to the medical community. Breast Cancer is the number one cause of death in women aged 35-54, and we believe that a woman’s best defense against breast cancer is early detection. Therefore, the Trihealth Breast Program has adopted The American College of Radiology’s guidelines for screening mammography, which is to begin screening at age 40 for women of average risk, and annually thereafter if otherwise healthy. Other organizations that promote screening at 40 include: American College of Obstetrics and Gynecology (ACOG), Society of Breast Imaging (SBI), American Medical Association (AMA), American Society of Breast Surgeons (ASBrS) and National Comprehensive Cancer Network (NCCN).

 

We are excited to announce the addition of 3D mammography at our Glenway location, as well as an additional 3D installation at our Good Samaritan Breast Center. We will also be installing a second 3D mammography unit at our Butler County location this spring. We now proudly offer 3D at the following locations:

Breast cancer screening has improved significantly in recent years with the advent of 3D mammography, or digital breast tomosynthesis (DBT), which offers better image quality and more data than ever before. But while DBT offers patients a number of benefits, such as improved cancer detection, fewer false positives and unnecessary recalls, it yields an exponential increase of images compared to 2D mammography, which can increase the daily workload for radiologists by almost two-fold.

 

Thanks to generous funding from the Bethesda Foundation, TriHealth is the first in the Tri-State area to recently adopt new technology that further maximizes the advantages of DBT and offers a transformative solution to address this emerging challenge as breast cancer screening technology evolves. ProFound AI for Digital Breast Tomosynthesis™ is the first and only FDA-cleared 3D tomosynthesis software using artificial intelligence (AI). It is the only software of its kind that offers clinically proven patient advantages over DBT alone, including:

We are proud to offer this technology enterprise wide.

 

You may have seen in the news recently that some patients are experiencing short term axillary lymphadenopathy after receiving the Moderna or Pfizer COVID vaccine. This can mimic an abnormal finding on breast imaging. The Trihealth Breast Program is following the recommendation of the American Society of Breast Imaging regarding timing for screening mammograms. Women should schedule their screening mammogram prior to receiving the vaccine or wait at least 4 to 6 weeks after their second injection. Our recommendation is the same for screening breast MRI. If patients are having a problem, they should not delay care; however, it is still important that patients inform the technologist of their recent vaccination, including which arm the injection was given. Please call 865-5997 if you have any questions regarding these recommendations.